Alice Melão,  —

Articles by Alice Melão

Prolong Pharma’s Sanguinate Shows Promise in Reverting Shape of Red Blood Cells in SCD

Prolong Pharmaceuticals’ investigational drug for treatment of sickle cell disease (SCD)-associated complications, Sanguinate, showed promising results in patients experiencing vaso-occlusive crisis (VOC). According to the research study, “SANGUINATE Returns RBCs To More Normal Morphology In Patients With VOC,” presented at the 2017 Annual Symposium of the Foundation…

Researchers Propose a New Subtype of SCD, Dyslipidemic, Based on Abnormal Lipid Profile

Brazilian researchers suggest that a new clinically relevant subgroup of sickle cell disease (SCD) should be considered, based on hematological and biochemical parameters in patients with SCD. Determination of classical biomarkers and lipid parameters can contribute to a better definition of this complex disease and improve patient’s clinical care, they concluded. Their…

Animal Models Help with Studies of Sickle Cell, But More Needed, Review Says

The β-hemoglobin gene and protein in humans and mice are similar, which makes a laboratory mouse a very useful partner in studies of β-hemoglobin-related disorders, like sickle cell disease, and possible treatment targets. A review looked at the benefits and shortcomings of animal models of β-hemoglobin diseases, and suggested that the time had come to move “beyond” them.